NurExone Biologic Inc. is a publicly-traded biopharmaceutical company, listed on the Toronto Stock Exchange and Frankfurt Stock Exchange (TSXV: NRX) (FSE: J90) The company is developing and commercializing an exosome therapy “ExoTherapy” production platform and products for a global market projected at $5.2 billion dollars.

The Company operates according to two business lines:
  • Development of ExoPTEN, a first ExoTherapy-based product for acute Spinal Cord Injuries (SCI).
  • Monetization of its proprietary ExoTherapy technology and production platform through licensing to the global biopharmaceutical industry for other diseases and indications

Set layout popup